ALK and lung adenocarcinoma: Taken together, these biochemical and clinical studies strongly implicate the down regulation of DUSP6/MKP-3 as a driver of ERK-dependent resistance to TKI therapy in ELM4–ALK positive lung adenocarcinomas [52].